Therapy‐related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis

Acute lymphoblastic leukemia (ALL) occurring in patients with a history of prior chemotherapy/radiotherapy exposure has been previously reported to be rare, accounting for <2.5% of ALL cases.

[1]  S. Bhatia,et al.  Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Minden,et al.  Treatment of adults with BCR‐ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen , 2009, British journal of haematology.

[3]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[4]  G. Wilding,et al.  Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Hong Chang,et al.  CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. , 2007, Leukemia research.

[6]  H. Dombret,et al.  Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study , 2006, Leukemia.

[7]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[8]  H. Kantarjian,et al.  Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.

[9]  E. Estey,et al.  Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. , 2004, Blood.

[10]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[11]  M. Slovak,et al.  High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities , 2003, Leukemia.

[12]  A. Levis,et al.  Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia , 2001, British journal of haematology.

[13]  L. Mele,et al.  Clinical and Epidemiological Features of Acute Lymphoblastic Leukemia Following a Previous Malignancy , 2000, Leukemia & lymphoma.

[14]  P. Hall,et al.  Risk of leukemia after platinum-based chemotherapy for ovarian cancer. , 1999, The New England journal of medicine.

[15]  Endi Wang,et al.  Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review. , 2010, American journal of clinical pathology.

[16]  F. Mandelli,et al.  Acute leukemia following a previous malignancy: do acute lymphoid leukemia and acute myeloid leukemia have common risk factors? , 2000, The hematology journal : the official journal of the European Haematology Association.